Tuberculosis News and Research

Latest Tuberculosis News and Research

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

Pfizer Inc. announced today that tofacitinib has been approved for the treatment of rheumatoid arthritis in patients who had an inadequate response to existing therapies in several additional countries around the world, including Switzerland, which is the first European country to receive approval.

15 Jul 2013

University of North Carolina receives $8M grant to improve maternal and infant health

The University of North Carolina at Chapel Hill has received a five-year, $8 million grant from the Bill & Melinda Gates Foundation to improve maternal and infant health and save the lives of mothers and infants in Malawi by strengthening the President's Maternal Health and Safe Motherhood Initiative (SMI).

11 Jul 2013

Study identifies new groups of people at risk of parasitic lung infection

A study conducted by Dr. James Diaz, Professor of Public Health and Preventive Medicine and Program Director of the Environmental/Occupational Health Sciences Program at the LSU Health Sciences Center New Orleans School of Public Health, analyzed cases of a parasitic lung infection and found new modes of transmission and associated behaviors, identifying new groups of people at risk.

11 Jul 2013

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

Immune response to TB bacterium varies between patients of different ethnic origin

The immune response to the bacterium that causes tuberculosis (TB) varies between patients of different ethnic origin, raising important implications for the development of tests to diagnose and monitor treatment for the disease, according to new research published today in the journal PLOS Pathogens.

5 Jul 2013

Collaborative research yields a wiring map on how TB responds to changes in environment

Despite decades of research on the bacterium that causes tuberculosis (TB), scientists have not had a comprehensive understanding of how the bacterium is wired to adapt to changing conditions in the host.

5 Jul 2013

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

University of Adelaide research has produced a potential new antibiotic which could help in the battle against bacterial resistance to antibiotics.

4 Jul 2013

Cannabis users appear to lack motivation

Researchers found that dopamine levels in a part of the brain called the striatum were lower in people who smoke more cannabis and those who began taking the drug at a younger age.

2 Jul 2013

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society Conference, include new antiretroviral therapy recommendations for HIV-infected children, and will mean that more children will be on better treatments.

1 Jul 2013

New WHO guidelines recommend earlier treatment for people living with HIV

New HIV treatment guidelines by WHO recommend offering antiretroviral therapy earlier. Recent evidence indicates that earlier ART will help people with HIV to live longer, healthier lives, and substantially reduce the risk of transmitting HIV to others.

1 Jul 2013

Nano and laser technology packed into small device tests antibiotic treatment in minutes

Researchers at EPFL have built a matchbox-sized device that can test for the presence of bacteria in a couple of minutes, instead of up to several weeks. A nano-lever vibrates in the presence of bacterial activity, while a laser reads the vibration and translates it into an electrical signal that can be easily read-the absence of a signal signifies the absence of bacteria.

1 Jul 2013

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen Biotech, Inc. and Johnson & Johnson Innovation announced today the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next generation therapeutic solutions.

27 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Scientists discover new drug that cripples TB bug by dissolving its protective fatty coating

Most humans would like to shed their fatty exteriors, but tuberculosis (TB)-causing bacteria rely on theirs for survival. Scientists at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School have now discovered a drug that cripples the TB bug by dissolving its protective fatty coating, a finding that could eventually be used to improve TB treatment in humans. The study has been posted online by Nature Chemical Biology.

19 Jun 2013

Endosonographic aspiration procedures result in greater diagnostic yield in treating pulmonary sarcoidosis

Among patients with suspected stage I/II pulmonary sarcoidosis who were undergoing confirmation of the condition via tissue sampling, the use of the procedure known as endosonographic nodal aspiration compared with bronchoscopic biopsy, the current diagnostic standard, resulted in greater diagnostic yield, according to a study in the June 19 issue of JAMA.

19 Jun 2013

Scientists discover new anti-tuberculosis compound that kills drug-resistant TB bacteria

An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.

18 Jun 2013

TSRI scientists identify highly promising new anti-tuberculosis compound

An international team led by scientists at The Scripps Research Institute, the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis bacterium in two different ways.

18 Jun 2013

Malaria control strategies: an interview with Sir Richard Feachem, Global Health Group, University of California, San Francisco

Exciting progress has been made in the global fight against malaria. The malaria map continues to shrink each year; in the last ten years four countries have been certified malaria-free, and thirty-four additional countries are now working towards malaria elimination targets.

17 Jun 2013

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.

15 Jun 2013

Tuberculosis News and Research

Latest Tuberculosis News and Research

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Pfizer announces approval of tofacitinib for treatment of rheumatoid arthritis

University of North Carolina receives $8M grant to improve maternal and infant health

Study identifies new groups of people at risk of parasitic lung infection

Seattle researchers map critical molecules that regulate inflammation during flu infection

Immune response to TB bacterium varies between patients of different ethnic origin

Collaborative research yields a wiring map on how TB responds to changes in environment

Researchers produce potential antibiotic that targets bacterial enzyme critical to metabolic processes

Cannabis users appear to lack motivation

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

New WHO guidelines recommend earlier treatment for people living with HIV

Nano and laser technology packed into small device tests antibiotic treatment in minutes

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Scientists discover new drug that cripples TB bug by dissolving its protective fatty coating

Endosonographic aspiration procedures result in greater diagnostic yield in treating pulmonary sarcoidosis

Scientists discover new anti-tuberculosis compound that kills drug-resistant TB bacteria

TSRI scientists identify highly promising new anti-tuberculosis compound

Malaria control strategies: an interview with Sir Richard Feachem, Global Health Group, University of California, San Francisco

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Tuberculosis News and Research

Latest Tuberculosis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in